{"id":"4d12cacd-b7b1-51c7-937f-cfd6be20964c","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-the-anticancer-effect-is-tubulin","predicate":"inhibits","statement":"The effective concentrations of mebendazole to inhibit GL261 glioblastoma cell viability, microtubule polymerization and metaphase arrest were very similar, and using mebendazole as a seed for the NCI COMPARE program revealed that the top-scoring drugs were highly enriched in microtubule-targeting drugs, indicating that the cell toxicity of mebendazole is indeed caused by inhibiting microtubule formation.","claim_class":"mechanistic","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"c6ed1f7c-a648-5f84-962d-07be16b074ec","mechanism_event_label":"The concentration that kills the cell is the concentration that blocks its microtubules, so it is the same mechanism.","subject":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"object":{"id":"32b8890f-3542-5709-bf8b-31247187e059","slug":"mitotic-arrest","display_name":"Mitotic arrest","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"c6ed1f7c-a648-5f84-962d-07be16b074ec","stable_key":"f2ec2007-88ff-5a96-a73b-8b5085e9cea9:mbz-the-anticancer-effect-is-tubulin-event","event_type":"biochemical_relationship","label":"The concentration that kills the cell is the concentration that blocks its microtubules, so it is the same mechanism.","description":"The effective concentrations of mebendazole to inhibit GL261 glioblastoma cell viability, microtubule polymerization and metaphase arrest were very similar, and using mebendazole as a seed for the NCI COMPARE program revealed that the top-scoring drugs were highly enriched in microtubule-targeting drugs, indicating that the cell toxicity of mebendazole is indeed caused by inhibiting microtubule formation.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"011e92dc-f29a-5ed1-bc3e-942ffc6664bb","slug":"microtubule-polymerisation","display_name":"Polymerisation of tubulin into microtubules","entity_type_key":"cellular_process"},"role":"inhibited_process","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"4435d112-8e28-5fe8-9bf6-61e95b3a0ac2","slug":"nci-compare-profile","display_name":"The NCI COMPARE activity-profile comparison","entity_type_key":"cellular_process"},"role":"supporting_analysis","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"3394b04b-6dc0-528b-8e94-0644d5d33f45","slug":"mammalian-brain-tubulin","display_name":"Mammalian brain tubulin","entity_type_key":"protein"},"role":"off_target_now_target","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"f8582a13-fc2e-5127-a61f-5b0594e54069","slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"32b8890f-3542-5709-bf8b-31247187e059","slug":"mitotic-arrest","display_name":"Mitotic arrest","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/mebendazole-research/28386621.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"20ef610d6b4a341f8a0a3f731bbea5477badbee517062c303bbf1075f3a29865\", \"start_char\": 0, \"end_char\": 1788, \"text_sha256\": \"20ef610d6b4a341f8a0a3f731bbea5477badbee517062c303bbf1075f3a29865\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Concentration-matched comparison of viability, microtubule polymerisation and metaphase arrest, with NCI COMPARE analysis and a head-to-head animal comparison against vincristine","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Mebendazole against vincristine close to its maximum tolerated dose in orthotopic GL261 tumours","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Tests whether the anticancer effect is the microtubule effect by matching concentrations across three assays, which most repurposing studies do not do.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.","comparator":null,"unit":null,"notes":"","entity":{"slug":"mebendazole","display_name":"Mebendazole","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Mouse","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"The concentration that kills the cell is the concentration that blocks its microtubules, so it is the same mechanism.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[mbz-p28386621] Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. (2017). https://pubmed.ncbi.nlm.nih.gov/28386621/ DOI: 10.2119/molmed.2017.00011","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Glioblastoma","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"8b269aa2-15a8-5e7b-87fa-a6dd3397bd30","evidence_kind":"source_excerpt","locator":"Lines 498-509","start_line":498,"end_line":509,"excerpt":"### mbz-the-anticancer-effect-is-tubulin\nThe effective concentrations of mebendazole to inhibit GL261 glioblastoma cell viability, microtubule polymerization and metaphase arrest were very similar, and using mebendazole as a seed for the NCI COMPARE program revealed that the top-scoring drugs were highly enriched in microtubule-targeting drugs, indicating that the cell toxicity of mebendazole is indeed caused by inhibiting microtubule formation.\nCondition category: normal\nnutrient_topic: Mebendazole research collection; topical membership is not evidence of a direct clinical effect, and mebendazole is recorded separately from albendazole, from the benzimidazole class and from its own crystal forms.\nplain_language: The concentration that kills the cell is the concentration that blocks its microtubules, so it is the same mechanism.\norganism: Mouse\ntissue_or_cell_type: Glioblastoma\nexperimental_model: Concentration-matched comparison of viability, microtubule polymerisation and metaphase arrest, with NCI COMPARE analysis and a head-to-head animal comparison against vincristine\nlimitations: Tests whether the anticancer effect is the microtubule effect by matching concentrations across three assays, which most repurposing studies do not do.\nexposure: Mebendazole against vincristine close to its maximum tolerated dose in orthotopic GL261 tumours\nevidence_span: {\"source_cache\": \"artifacts/mebendazole-research/28386621.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"20ef610d6b4a341f8a0a3f731bbea5477badbee517062c303bbf1075f3a29865\", \"start_char\": 0, \"end_char\": 1788, \"text_sha256\": \"20ef610d6b4a341f8a0a3f731bbea5477badbee517062c303bbf1075f3a29865\"}\n[mbz-p28386621] Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. (2017). https://pubmed.ncbi.nlm.nih.gov/28386621/ DOI: 10.2119/molmed.2017.00011","model_system":"Concentration-matched comparison of viability, microtubule polymerisation and metaphase arrest, with NCI COMPARE analysis and a head-to-head animal comparison against vincristine","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [mbz-p28386621] Repurposing Mebendazole as a Replacement for Vincristine for the Treatment of Brain Tumors. (2017). https://pubmed.ncbi.nlm.nih.gov/28386621/ DOI: 10.2119/molmed.2017.00011","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"06104773-03d0-5e5c-b9da-eb484e7be657","stable_key":"import-f2ec2007-88ff-5a96-a73b-8b5085e9cea9","title":"Mebendazole: the tubulin it binds, why that is selective, the crystal form that decides whether any of it works, and the off-target that became an oncology programme (2026-09-22)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"58b652636677e5033fd1dd555744485fcef18f21a97dcf68723fe072b656f413","revision_id":"a2cd9c22-0549-52ca-a653-8a0c2362ec85","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}